Ongoing or recent (within 5 years) evidence of autoimmune disease that required treatment with systemic immunosuppressive treatments;
Has active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Active autoimmune disease that has required systemic treatment in past 2 years.
Has an active autoimmune disease that has required systemic treatment in the past 2 years (eg, with use of disease-modifying agents, anticoagulants, corticosteroids or immunosuppressive drugs).
Active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease that has required systemic treatment within the last 2 years.
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Has an active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease that has required systemic treatment in past 2 years
Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)
Has an active autoimmune disease that has required systemic treatment in the past 2 years.
Autoimmune disease that required systemic treatment
Active autoimmune disease that has required systemic treatment in the past 2 years
Has active autoimmune disease that has required systemic treatment in past 2 years.
Active autoimmune disease including active diverticulitis, symptomatic peptic ulcer disease, colitis, or inflammatory bowel disease that has required systemic treatment in past 2 years
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy is allowed.
Active autoimmune disease that has required systemic treatment in past 2 years.
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Has active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease that has required systemic treatment in the past 2 years
Has active or prior autoimmune disease within the past 2 years
Subject has an active autoimmune disease that has required systemic treatment within the past 2 years.
Has active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Active or inactive autoimmune disease or syndrome that has required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease.
Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)
Active autoimmune disease that has required systemic treatment in past 2 years.
Has active autoimmune disease that required systemic treatment with use of disease modifying agents, corticosteroids or immunosuppressive drugs
Active autoimmune disease that has required systemic treatment in past 2 years
Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs.
Has an active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease requiring systemic treatment in past 2 years.
Active autoimmune disease that has required systemic treatment in past 2 years
Active or prior documented autoimmune disease within the past 2 years
Active autoimmune disease that has required systemic treatment in past 2 years.
Has an active autoimmune disease that has required systemic treatment in the past 2 years.
Active autoimmune disease that required systemic treatment in the past 2 years
Active autoimmune disease requiring systemic treatment within the past 2 years
Has an active autoimmune disease requiring systemic treatment within the past 2 years OR a documented history of clinically severe autoimmune disease.
Has active autoimmune disease that has required systemic treatment in past 2 years.
History of any autoimmune disease which required systemic therapy in the past 2 years
Evidence of other active autoimmune disease that has required prolonged systemic treatment in past 2 years.
Active autoimmune disease that has required systemic therapy in the past 2 years with modifying agents, corticosteroids, or immunosuppressive agents
Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed)
Active autoimmune disease that has required systemic treatment in past 2 years.
Active autoimmune disease that has required systemic treatment in past 2 years.
Active autoimmune disease that has required systemic treatment in past 2 years.
Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)
Active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease requiring systemic treatment in the past 2 years
Has active autoimmune disease that has required treatment in the past 2 years.
Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed)
Active autoimmune disease that required systemic treatment in the past. Patients who have not required systemic treatment for at least two years may be enrolled if permission is provided after discussion with the Medical Monitor.
Active, known, suspected autoimmune disease requiring systemic treatment in the past 2 years
Has active or prior documented autoimmune disease within the past 24 months
Has active autoimmune disease that has required systemic treatment within the 2 years prior to the first dose of study medication
Active autoimmune disease that has required systemic treatment in past 2 years .
Active autoimmune disease requiring systemic treatment in past 2 years
Active autoimmune disease that has required systemic treatment in past 2 years (replacement therapy is not considered a form of systemic treatment
Active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment
Active or prior documented autoimmune disease within the past 2 years
Active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease that has required systemic therapy in the past 2 years with modifying agents, corticosteroids, or immunosuppressive agents
Active or prior documented autoimmune disease within the past 2 years.
Has an autoimmune disease that has required systemic treatment in the past 2 years with use of disease modifying agents, corticosteroids, or immunosuppressive drugs
Active or prior documented autoimmune disease within the past 2 years
Autoimmune disease that has required systemic treatment in past 2 years
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment.
Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Has an active autoimmune disease that has required systemic treatment in past 2 years
Active autoimmune disease that has required systemic treatment in the past 3 months.
Active or prior documented autoimmune disease within the past 3 years
Active or prior documented autoimmune disease within the past 2 years
Active or prior documented autoimmune disease within the past 2 years
Active or prior autoimmune disorder within the past 2 years
Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments
Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment.
Active autoimmune disease requiring systemic therapy in past 2 years (IMGN853 and pembrolizumab only)
Has an active autoimmune disease that has required systemic treatment in past 2 years.
History or evidence of active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
Active autoimmune disease that required systemic treatment in the past.
Has an active autoimmune disease that has required systemic treatment in the past 2 years (e.g., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
Active autoimmune disease that required systemic treatment in the past 2 years
Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with the use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
Any active autoimmune disease or a documented history of serious autoimmune disease within the past 5 years requiring immunosuppressive therapy.
Patients with autoimmune disease who are otherwise eligible must not have received steroid and immunosuppressive therapy within 28 days prior to registration
Active autoimmune disease requiring disease-modifying therapy at the time of Screening.
Primary or secondary immunodeficiency (including immunosuppressive disease, autoimmune disease [including autoimmune endocrinopathies, such as hypothyroidism, and insulin dependent diabetes mellitus], or usage of immunosuppressive medications).
Patients with chronic autoimmune disease(s) requiring systemic immunosuppression.
Subject has active, suspected, or previously documented autoimmune disease, defined as requiring systemic treatment.
Active autoimmune disease requiring immunosuppressive therapy
Patient with active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications .
Active autoimmune condition requiring systemic immunosuppressive medication
Patients cannot have active autoimmune disease or immunosuppressive conditions
Patients with active autoimmune disease, requiring ongoing immunosuppressive therapy or history of transplantation
History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment
Uncontrolled autoimmune disease requiring active systemic treatment
Patients with active clinically significant autoimmune disease, defined as a history of requiring systemic immunosuppressive therapy and at ongoing risk for potential disease exacerbation. Patients with a history of autoimmune thyroid disease, asthma, or limited skin manifestations are potentially eligible.
Active autoimmune disease requiring systemic steroids or immunosuppressive agents within 7 days prior to study entry
Active autoimmune disease requiring immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring ongoing systemic immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy.
Current autoimmune disease requiring >= 20 mg/day of prednisone or systemic immunosuppressive therapy (eg. with cyclosporine or azathioprine).
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: Active autoimmune disease requiring immunosuppressive therapy, unless considered by the PI or designee to be eligible
Active autoimmune disease requiring systemic immunosuppressive therapy
Active auto-immune disease including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive therapy
History of autoimmune disease, requiring systemic immunosuppression and/or systemic disease modifying agents within the last 2 years
Active autoimmune diseases requiring systemic treatments
Active autoimmune disease and chronic inflammatory conditions requiring concurrent use of any systemic immunosuppressants or steroids.
Have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
Prior organ transplant or autoimmune disease requiring immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive therapy
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Active autoimmune disease requiring immunosuppressive therapy
EXCLUSION CRITERIA FOR TNBC: Active autoimmune disease requiring immunosuppressive therapy
Active autoimmune disease requiring disease-modifying therapy
History of severe autoimmune disease requiring steroids or other immunosuppressive treatments
Subjects must not have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
Have any active disease requiring systemic immunosuppressive treatment
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the Principal Investigator (PI)
Known autoimmune disease requiring active treatment.
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive treatment or history of autoimmune disease requiring immunosuppressive therapy (e.g. requirement for systemic therapy with >10 mg/day prednisone-equivalent) or any other concurrent use of immunosuppressive therapy.
Active autoimmune disease requiring systemic immunosuppressive therapy
Participants that have experienced active autoimmune disorders requiring cytotoxic or immunosuppressive therapy within the 6 weeks (42 days) prior to consenting\r\n* The following will not be exclusionary:\r\n** The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody [ANA] titer) without symptoms\r\n** Clinical evidence of vitiligo\r\n** Other forms of depigmenting illness\r\n** Mild arthritis requiring nonsteroidal antiinflammatory drug (NSAID) medications
Current or history of systemic autoimmune disease requiring systemic therapy\r\n* NOTE: The following will not be exclusionary: \r\n** The presence of laboratory evidence of autoimmune disease (e.g., positive ANA titer) without associated symptoms \r\n** Clinical evidence of vitiligo \r\n** Other forms of depigmenting illness
Active (as defined by requiring immunosuppressive therapy) or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy)
Active autoimmune disease requiring systemic immunosuppressive therapy
Patients with a history of autoimmune disease that require immunosuppressive medications at the time of screening are excluded
Active autoimmune disease requiring treatment
Active or history of any autoimmune disease (except for subjects with vitiligo) or immunodeficiencies that required treatment with systemic immunosuppressive drugs
No disease requiring systemic immunosuppressive therapy
Active or prior autoimmune disease except for autoimmune thyroiditis, vitiligo, or psoriasis not requiring systemic therapy
Active autoimmune disease requiring disease modifying therapy
Patients with active autoimmune disease requiring disease-modifying therapy.
Subjects with active autoimmune disease requiring systemic immunosuppressive treatment within the past 4 weeks such as but not restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis; a history of autoimmune disease which is not active nor has required recent systemic immunosuppressive therapy (< 4 weeks prior to enrollment) is not reason for exclusion
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune/inflammatory conditions requiring ongoing immunosuppressive therapy
Patients with any clinically significant autoimmune disease requiring active treatment
Prior allogeneic transplant 7. History of severe autoimmune disease requiring steroids or other immunosuppressive treatments.
Active autoimmune disease currently requiring therapy
Any immunodeficiency disease or immunocompromised state or active autoimmune disease or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
History of severe autoimmune disease requiring steroids or other immunosuppressive treatments
Patients with active autoimmune disease requiring disease-modifying therapy.
Subjects with active autoimmune disease or a history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment.
Active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications;
DONOR: Autoimmune disease requiring immunosuppressive drugs for maintenance
Any active autoimmune disease requiring treatment (e.g. steroid, disease-modifying antirheumatic drugs, biologic agents, etc.)
Active autoimmune disease, symptoms or conditions except for vitiligo, type I diabetes, treated thyroiditis, asymptomatic laboratory evidence of autoimmune disease (e.g.: +ANA, +RF, antithyroglobulin antibodies), or mild arthritis requiring no therapy or manageable with NSAIDs.
Active autoimmune disease or condition requiring chronic immunosuppressive therapy
Autoimmune disease requiring immunosuppressive drugs for maintenance
DONOR: Autoimmune disease requiring immunosuppressive drugs for maintenance
Known history or evidence of brain metastases, immunodeficiency disease or immunocompromised state or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
No active (as defined by requiring immunosuppressive therapy) or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy)
Any immunodeficiency disease or immunocompromised state or active autoimmune disease or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
Active autoimmune disease requiring disease modifying therapy
Patients with active autoimmune conditions requiting systemic immunosuppressive therapy within the previous 5 years at not eligible
Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible
Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible
Any active autoimmune disease requiring treatment, with the exception of vitiligo
Active autoimmune disease requiring systemic immunosuppressive therapy (standard of care [SOC] GVHD prophylaxis is permitted)
Known immunosuppressive disease, autoimmune conditions, and /or chronic viral infections
Autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment
Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 75% or greater
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
STEP I: Prior systemic glucocorticoid use for the treatment of non-malignant disorders is permitted; prior or concurrent topical or localized glucocorticoid therapy to treat non-malignant comorbid disorders is permitted
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Recurrent or multifocal malignant gliomas
Patients must have had cytology within 21 days prior to registration; cytology for patients with CIS component is not expected to be negative for malignant cells; if the cytology for patients with only Ta/T1 disease is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months
Any evidence of tumor metastasis or co-existing malignant disease
Malignant disease, other than that being treated in this study.
Other malignant diseases than the ones being treated in this study
Malignant disease, other than that being treated in this study.
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Malignant CNS disease that has not been definitively treated
Malignant disease, other than that being treated in this study
Patients with malignant disease other than that being treated in the study.
Participants may have underlying malignant or non-malignant hematologic disease, except for primary immunodeficiency, as the indication for their allogeneic HSCT; patients with immune dysregulation syndromes such as familial or secondary hemophagocytic lymphohistiocytosis (HLH) are eligible
Known distant metastatic disease (e.g. pulmonary or hepatic metastases)\r\n* Subjects with malignant lymphadenopathy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadnectomy with the goal of complete resection of all malignant disease are allowed
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years
Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugs
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug
Progressive underlying malignant disease or any post-transplant lymphoproliferative disease
Concurrent, malignant disease for which patient is on active therapy
A history of pneumonitis or extensive bilateral lung disease of non-malignant etiology.
All malignant disease must be able to be encompassed within a single irradiation field
Less than 5% malignant cells in the peripheral blood leukocytes
More than one concurrent, malignant disease
Visible additional disease that suggests a greater than T2 malignant melanoma
Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea
Active malignant relapse
Another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
Less than 5% malignant cells in the peripheral blood leukocytes
Malignant disease other than that being treated in this study.
These procedures are commonly performed in patients with malignant neoplasms, malignant neuroendocrine tumors, or carcinomas in situ, and are commonly “tracked” by hospitals and cancer centers participating in the ACS NSQIP Procedure Targeted option because they are often associated with higher rates of postoperative morbidity and mortality (compared to other, less complex cancer procedures)
Cohort 1: Any solid malignant tumor.
INCLUSION CRITERIA FOR ENROLLMENT: Expectation of ability to safely undergo salvage treatment appropriate for the patient’s malignant disease type
INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Expectation of ability to safely undergo salvage treatment appropriate for the patient’s malignant disease type
patients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.
Patient is diagnosed with benign or malignant stricture, fistula, perforation, or leak
Must not have an advanced malignant hepatic tumor
Histologic proof of phyllodes tumor of borderline or malignant grade, as first defined by Pietruszka and modified by Azzopardi and adopted by the World Health Organization:\r\n * Borderline malignant: 5-9 mitoses/10 high-power fields (HPF), pushing or infiltrating margins, 2+ (moderate) stromal cellularity and atypia\r\n * Malignant: 10 or more mitoses/10 HPF, predominantly infiltrating margins, usually 3+ (severe) stromal cellularity and atypia but occasionally 2+
INCLUSION CRITERIA FOR CCT: patients must have the diagnosis of malignant chromaffin cell tumor (CCT) i.e. malignant pheochromocytoma or malignant paraganglioma
Malignant disease, other than that being treated in this study
Patients with M1 stage according to the Tumor, Node and Metastasis Classification of Malignant Tumours (TNM)
Patients with a history of cancer that has been completely treated, with no evidence of malignant disease currently cannot be enrolled in the study if their chemotherapy was completed less than 6 months prior and/or have received a bone marrow transplant less than 2 years before the first day of study treatment
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea
Presence or history of a malignant disease other than the study related cancer
Subjects diagnosed with other malignant primary tumor
Another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
Malignant disease, other than that being treated in this study.
In addition, patients with NF1 and with malignant peripheral nerve sheath tumor (MPNST)
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Recurrent malignant gliomas
Other non-malignant systemic disease that would preclude treatment with any of the treatment regimens or would prevent required follow-up
A prospective patient for allogeneic hematopoietic stem cell transplant (HSCT) for hematologic conditions, both malignant and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient with history of central nervous system (CNS) involvement is eligible if CNS disease is in remission at time of study consideration
Existing non-malignant disease that would preclude the administration of pasireotide
Patients with any non-malignant intercurrent illness (e.g. cardiovascular, pulmonary, central nervous system disease) which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the patient on protocol
Epithelioid malignant peripheral nerve sheath tumor
Epithelioid malignant peripheral nerve sheath tumor
Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted
Cytogenetic abnormalities finding in malignant myeloma clone with t(4; 14); and / or del(17p); and / or 1q amplification; and / or t(14:16);or
Cytogenetic abnormalities finding in malignant myeloma clone with t(4; 14); and / or del(17p); and / or 1q amplification; and / or t(14; 16); or
Diagnosis of malignant disease within the previous 12 months
Prior or concurrent malignant disease unless cured for more than five years.
Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of brain metastases
Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 12 months before the first dose of any study drug, except for hydroxyurea.
Any other malignant disease
Concurrent, malignant disease for which patient is on active therapy
Malignant disease, other than that being treated in this study
Evidence of recurrent or progressive underlying malignant disease
Evidence of recurrent or progressive underlying malignant disease
Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown malignant potential'.
Active malignant relapse
Participants with active malignant relapse or recrudescence of their prior hematologic disorder
Extension of malignant disease into the anal canal
Progressive underlying malignant disease including post-transplant lymphoproliferative disease.
Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months
Patients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.
Known history of malignant hypertension
All malignant disease must be able to be encompassed within a single irradiation field
Any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy
Prior investigational agents for malignant or non-malignant disease within 4 weeks prior to Day 1
Patient concurrently has another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
History of malignant peripheral nerve sheath tumor
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Known history of malignant hypertension.
Another active primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
12 Known history of malignant hypertension.
Prior gastrectomy (partial or total) for the underlying malignant disease under investigation
Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-up
Does not have any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy
Documented diagnosis of the following: Myelodysplastic syndrome lasting ? 3 months and < 3 years Disease must not be secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases
No other drug treatment for malignant melanoma administered after completing study treatment with trametinib
Evidence of an optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapy
Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT
Alkaline phosphatase > 1.5 x ULN (unless due to lymphoma or a non-malignant, non-hepatic cause such as Paget's disease)
Presence of GI disease, malignant tumors or other conditions known to interfere with ADME
Non-malignant disease that would render the patient unsuitable for treatment according to the protocol.
Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study drugs
Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.
Women with non-palpable malignant lesions, requiring image guided localization.
With diagnosis of malignant or benign disease
Is known or suspected to have a (family) history of malignant hyperthermia
Patients undergoing myeloablative allogenic hematopoietic stem cell transplant for any indication (both malignant and non-malignant) are eligible
Malignant pancreatic disease
TRANSPLANT PATIENTS: all patients undergoing planned allogeneic transplant (both malignant and non-malignant diagnoses)
Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
Evidence of active malignant disease
History of neuroleptic malignant syndrome
Active malignant disease relapse
Active malignant relapse
Known malignant primary brain tumor
Known primary benign or malignant hematologic disorder which can cause anemia.
Men with current anal disease diagnosed by a doctor (e.g., condyloma, hemorrhoids, fissures or malignant tumors) will be excluded
Participants must not have evidence of active/recurrent malignant disease for a minimum of 6 months.
Participants must not have evidence of active/recurrent malignant disease for 6 months
Must be underdoing allogeneic or autologous HCT for a malignant or non-malignant disorder
Other concurrent clinically active malignant disease, requiring treatment
Active metastatic cancer in addition to malignant primary brain tumor
Prior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy)
Patient is considered a poor risk for surgery due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment options
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder)
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment; Note: Subjects with a history of early stage or locally advanced non-metastatic prostate cancer within 2 years of the start of study treatment may be included in the study
No malignancy (other than the one treated in this study) which required radiotherapy or systemic treatment within the past 5 years
Subject has another malignancy for which treatment is required.
Concurrent diagnosis of another malignancy if either systemic treatment or surgery is expected to be required within 2 years from study entry
Evidence within the last 2 years of another malignancy which required systemic treatment
Evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
Subject has a history of a malignancy (other than the disease under treatment in the study) within 5 years before first study treatment administration
The subject has had within 2 years before the start of study treatment evidence of another malignancy which required systemic treatment
Presence of malignancy (other than the one treated in this study) which required systemic treatment within the past 3 years
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
No malignancy (other than for which patient underwent transplant) which required radiotherapy or systemic treatment within the past 5 years
The participant has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
